Peripheral artery disease (PAD) is a common manifestation of systemic atherosclerosis associated with worse prognosis. 1, 2 It affects N27 million people across Europe and America. 3, 4 There are a number of proven therapies to reduce mortality among patients with PAD. 5 However, mortality remained high and risk stratification has received little attention, when compared with patients with coronary artery disease (CAD). 3, 6 The awareness among at-risk patients and the medical community of PAD remain relatively low. 3, 7 Therefore, predictors of mortality and identifying poor prognosis markers in patients with PAD are valuable.
The Duke Activity Status Index (DASI) is a simple 12-question self-assessment tool for estimating functional capacity. 8 The DASI score correlated well with peak oxygen uptake on exercise treadmill stress testing (Spearman r = 0.81, P b .0001) 8 and are validated measures of treadmill functional capacity measured in metabolic equivalent tasks (Spearman r = 0.31, P b .01). 9 The DASI score predicted adverse prognosis in a cohort of patients with various types of cardiac disease. [9] [10] [11] [12] [13] [14] Remarkably, the long-term prognosis of DASI measurements in stable patients with lower extremity PAD (LEAD) as well as the other PAD subtypes has not been elucidated. Here, we sought to determine the long-term prognostic value of estimating functional capacity using the DASI questionnaire in stable patients with PAD. If the DASI questionnaire predicts long-term prognosis, then clinicians could potentially use the DASI to identify patients with PAD who are at risk for adverse prognosis either in the office setting or in primary care clinics.
Methods

Study population
The Cleveland Clinic GeneBank study prospectively enrolled patients with a history of PAD who underwent elective coronary angiography in the absence of emergency conditions. All-cause mortality was prospectively tracked for 5 years using the Social Security Death Index and medical record review, confirmed by follow-up contact. All participants gave written informed consent, and the study was approved by the institutional review board.
Diagnosis validation of types of PAD
Peripheral artery diseases have been defined by the American College of Cardiology/American Heart Association and the European Society of Cardiology (Supplementary Table I) . 2, 4 In our cohort, the term PAD is used to encompass most non-coronary arterial territories including extracranial carotid artery stenosis (CAS), upper extremity artery stenosis, renal artery stenosis (RAS), and LEAD. Diseases of the aorta are not included. We indicated non-LEAD if primarily diagnoses were not LEADs, which included CAS, RAS, and upper extremity artery stenosis.
Laboratory testing and assessment of the DASI questionnaire
After informed consent was obtained from all patients, fasting blood samples were collected using EDTA tubes at the time of coronary angiography after arterial sheath access, but before the catheterization procedure or any drug administration (including heparin). The samples were then immediately processed and frozen at −80°C until analysis. Routine laboratory tests were performed, and samples were measured on the Abbott Architect platform (Abbott Laboratories, Abbott Park, IL). Myeloperoxidase (MPO) was measured using the cardioMPO assay kit (Cleveland HeartLab, Cleveland, OH). Complete blood count was measured using the ADVIA 120 Hematology System (Siemens Healthcare Diagnostics, Inc, Tarrytown, NY). The DASI questionnaire (Supplementary Table II) was completely assessed by welltrained research personnel at the time of coronary angiography as previously described, 12 and this questionnaire has been validated in a similar population.
9,15
Statistical analysis
Continuous data are presented as mean (standard deviation [SD]) or median (interquartile range [IQR] ) and compared with Student t test or nonparametric test when appropriate. Categorical variables are presented as number (%) and compared between groups with χ 2 tests. We divided DASI into quartiles. Kaplan-Meier analysis with Cox proportional hazards regression was used for the time-to-event analysis to determine hazard ratios (HRs), and 95% confidence interval (CI) for 5-year all-cause mortality were stratified according to DASI as a continuous variable (log-transformed per SD increase), as well as according to quartiles. Adjustments were made for individual traditional cardiovascular risk factors (age, sex, systolic blood pressure, diabetes mellitus, low-density and high-density lipoprotein cholesterol levels, and smoking status) and for log-transformed high-sensitivity C-reactive protein (hsCRP) levels, log-transformed estimated glomerular filtration rate (eGFR), log-transformed MPO, log-transformed white blood cell (WBC), and apolipoprotein A-1 (ApoA1) and apolipoprotein B (ApoB), to predict all-cause mortality. Net reclassification index and area under the receiver operating characteristic curve were calculated according to mortality risk estimated using Cox models adjusted for above-mentioned traditional risk factors with vs without DASI score as previously described. 16 Subgroups were stratified according to diagnosis subtype of PAD (LEAD and non-LEAD) as well as other baseline clinical and laboratory subgroups that might be affected for mortality risks. All analyses were performed using R 2.15.1 (Vienna, Austria). A P value b.05 was considered statistically significant.
Results
Baseline characteristics
The 935 patients with medical history of PAD were directly questioned by research personnel about past medical problems of non-CAD and/or history of or repair of aortic dissection/aneurysm. Importantly, we carefully reviewed the electronic medical record (including angiographic data) for validation of PAD diagnostic subtypes (all patients were seen by a cardiologist at Cleveland Clinic before the left heart catheterization). A confirmed diagnosis of PAD was based primarily on the type of PAD, based on reporting evidence of stenosis at the corresponding vasculature (Supplementary Table I, Figure 1 ). Of these, confirmed diagnosis data were not available for 14 patients, 50 patients did not have DASI data, and 100 patients with a diagnosis of aortic aneurysm were excluded. Consequently, 771 consecutive patients were included in this study. The baseline characteristics of our study cohort according to DASI score quartile are shown in Table I . Patients with a lower DASI score were significantly associated with an underlying history of diabetes, previous stroke, chronic obstructive pulmonary disease (COPD), or heart failure (HF) and having high levels of inflammatory biomarkers (hsCRP or MPO). There were no differences in medication use across DASI quartiles.
The baseline characteristics according to PAD diagnosis subtype are shown in Table II (Table II) . Moreover, the distribution of patients with LEAD and non-LEAD was not significantly different across DASI score quartiles ( Figure 2) .
Of the 771 patients, 393 patients had diagnosis of LEAD confirmed by an ankle-brachial index b0.9 (68.7%), duplex ultrasonography (7.1%), computed tomographic angiography (0.5%), magnetic resonance angiography (MRA; 0.5%), catheter-based radiocontrast angiography (CATH; 6.4%), prior angioplasty or stenting (8.4%), and prior surgical bypass graft (8.4%); 351 patients had diagnosis of CAS confirmed by duplex ultrasonography (83.8%), MRA (2.6%), CATH (3.4%), prior stenting (4%), and open carotid endarterectomy (6.3%); 15 patients had diagnosis with RAS confirmed by MRA (20%), CATH (53.3%), and prior stenting (26.7%); and 12 patients had upper extremity artery stenosis confirmed by CATH (41.7%) and prior angioplasty or stenting (58.3%) ( Figure 1 ).
Associations of DASI score and all-cause mortality
Over the 5-year follow-up, 208 (27%) deaths occurred in our cohort. Quartiles 1 to 4 in the DASI score had 83, 41, 48, and 36 deaths, respectively, by the end of follow-up. Figure 3 represents the Kaplan-Meier analysis of the DASI score stratified by quartiles, which illustrated a graded increase in risk of all-cause mortality observed with decreasing DASI score with log rank (P b .001). Importantly, the lowest DASI score quartile predicted a 3.2-fold increase in risk for all-cause mortality compared with the highest DASI score quartile (quartiles 1st vs 4th, unadjusted HR 3.23, 95% CI 2.19-4.75, P b .001) ( Table III) . The prognosis value of the DASI score was preserved when adjusted for traditional risk factors (adjusted HR 2.62, 95% CI 1.72-3.98, P b .001) or even plus eGFR and hsCRP (adjusted HR 2.09, 95% CI 1.36-3.23, P b .001), as well as after adjusting for traditional risk factor, ApoA1, ApoB, MPO, and WBC (adjusted HR 2.84, 95% CI 1.79-4.53, P b .001) ( Table III) . As a continuous variable in increments of 1 SD, an increased DASI score was associated with lower mortality risk at 5 years after adjustment for traditional risk factors (adjusted HR 0.67, 95% CI 0.56-0.79 per SD, P b .001). The inclusion of the DASI score to a model of traditional cardiovascular risk factors showed that a lower DASI score significantly incremental prognosis value (integrated discrimination (Table III) . Furthermore, in the subgroup of patients with CAS, lowest DASI score was still independently associated with increased 5-year mortality risk even after adjustment for traditional cardiac risk factors, eGFR, and hsCRP (adjusted HR 2.13, 95% CI 1.1-4.12, P = .025), as well as after adjusting for traditional risk Other abbreviations as in Table I .
factor, ApoA1, ApoB, MPO, and WBC (adjusted HR 2.58, 95% CI 1.27-5.25, P = .009). However, when adjusted for brain natriuretic peptide and left ventricular ejection fraction (LVEF), the mortality risk remained statistically significant only in the LEAD subset, whereas the non-LEAD group did not (Table III) . Importantly, subgroup analyses reveal that lowest DASI scores predict 5-year all-cause mortality regardless of each diagnosis subtype of PAD (between LEAD, non-LEAD, and CAS), age, sex, history of chronic obstructive lung disease, history of HF, present or absence of claudication symptoms, diabetes, smoking status, eGFR, and LVEF ( Figure 4 ).
Discussion
There are several key findings in our study. First, results reported here show, for the first time, that the lowest DASI score is associated with greater 5-year mortality in patients with established diagnosis of PAD. Second, this association remained robust after adjustment for confounders including traditional cardiac risk factor, eGFR, ApoA1, and ApoB and marker of systemic inflammation (hsCRP, MPO, and WBC). Meanwhile, the mortality risk was attenuated by confounding factors such as extent of coronary disease and cardiac dysfunction (Table III) . Third, when we performed the survival analyses separately according to diagnostic subtype of PAD, the lowest DASI score remained associated with long-term mortality risk in each subtype of PAD. Fourth, the prognosis value for lowest DASI score and mortality remained significant regardless of other comorbid conditions and laboratory subgroups.
Patients with PAD have significantly increased risk of adverse prognosis. 2, 17 As indicated in recently published clinical studies and clinical practice guideline in patients with PAD, few data are available to document the role of functional capacity and natural history among patients with non-LEAD. 2, 4 In addition, patients with LEAD are likely to have lower DASI score than non-LEAD. Interestingly, based on our findings, the prognostic value of the DASI score remained preserved in the subgroup of patients with either diagnosis of LEAD or non-LEAD, and the presence of equivalent baseline DASI score between patients with LEAD and non-LEAD. To our knowledge, this is the first study that assessed the association between lower baseline functional capacity, estimated by DASI score, and all-cause mortality, specifically in PAD patients with covered multiple vascular beds.
Previous studies have demonstrated that poorer baseline functional capacity, estimated by a 6-minute walk test and 4-meter walking velocity, were associated with higher mortality and mobility loss in patients with LEAD. 18, 19 Although both functional capacity assessment tools are useful in mortality risk prediction, they are objective measures that require dedicated time and space in the clinical setting. The lower baseline values of Walking Impairment Questionnaire (WIQ) stair-climbing score were associated with higher mortality in LEAD. 20 Unfortunately, the WIQ is quite complex, and patients need to answer 14 questions and each with 5-possible answers (5 different "difficulty graded scales") 21 and associated with a high rate of errors 22 whereas the DASI is a short, easily administered questionnaire with simple yes/no rather than direct recall of prior physical activities and/or limitations and is not time consuming or labor intensive.
There have been no studies that directly examined the potential use of DASI to predict long-term prognosis specifically in patients with PAD. However, the DASI has been validated in cohorts of patients with various types of cardiac disease. The Woman's Ischemia Syndrome Evaluation (WISE) study showed that the DASI correlates with indeterminate exercise testing results and is associated with an adverse prognosis among women with suspected myocardial ischemia.
14 Our group has previously reported that among patients with stable chronic HF and stable cardiac patients undergoing elective diagnosis cardiac evaluation, DASI provides independent and incremental prognostic value for mortality prediction. 10, 12 In the setting of cardiac surgery, Koch et al 13 demonstrated that lower DASI score at perioperative baseline and postoperative follow-up identifies patients who are at risk for reduced long-term survival, and those who achieved a maximum baseline DASI were associated with better risk-adjusted long-term survival. Recent data from the Trial of Intensified versus Standard medical therapy in Elderly patients With Congestive heart Failure (TIME-CHF) further implied that those with changes in DASI score within 1 year demonstrated stronger association with long-term outcomes than an objective assessment (6-minute walking distance). 23 Previous studies from the Walking and Leg Circulation Study (WALCS) cohort have reported that greater than 2-year declines in functional performance and WIQ scores were associated with higher all-cause mortality in patients with LEAD. 24, 25 Importantly, home-based walking exercise program improves WIQ and functional performance in patients with LEAD. 26 These findings are supportive of the ability to prevent decline or improving the DASI score as a potential therapeutic target in patients with PAD. Based on our findings, it seems reasonable to administer the estimated self-reported physical capacity by using the DASI in the daily clinical setting, either in the office or in primary care Relationship between DASI score and mortality risk stratified according to each diagnostic PAD subtype and baseline characteristics. Forest plot of HR of 5-year all-cause mortality comparing first and fourth quartiles of DASI score.
clinics. This would provide an effective tool for identification of those patients at highest long-term adverse event risk who should be targeted for more intensive follow-up and treatment. Further study is needed to determine whether interventions that improve the DASI score also improve prognosis among patients with PAD.
Study limitations
First, this was a single tertiary care center study that recruited patients at the point of cardiac catheterization; therefore, there were a higher proportion of patients with CAD. Second, our population consisted of a heterogeneous subgroup of patients with PAD; we addressed this issue by electronic record review to confirm diagnosis carefully captured individually, and the presence of equivalent baseline DASI score between LEAD and non-LEAD. Also, we separately performed survival analyses according to diagnosis subtype, as we excluded patients with LEAD, the lowest DASI score still associated with adverse prognosis. We believe that they may be generalized to all patients within the PAD cohort. Third, we lacked complete information regarding the severity of intermittent claudication and disease severity of each diagnosis subtype of PAD, but we addressed this issue by enrolling patients in stable condition. Fourth, although we adjusted for confounders, including comorbidities, we cannot exclude other reasons that affect an individual's functional limitation. We incorporated many disease severity measures that were available, but not all patients have LVEF measured or reported at the time of enrollment. Finally, DASI score was measured at only a single time point, and we were unable to determine if improvement in DASI score can be associated with improvement in short-and long-term prognosis or the impact of intervention can improving DASI score. Despite these limitations, our results demonstrate that simple subjective measures for estimating functional capacity using the DASI questionnaire can be used to identify patients with PAD who are at highest risk for long-term adverse event risk.
Conclusions
The DASI, a simple self-assessment tool of functional capacity, provides a strong independent and incremental prognosis value for long-term adverse event risk in patients with PAD. 
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